COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
Uložené v:
| Názov: | COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey |
|---|---|
| Autori: | Leonardo Santos Hoff, Naveen Ravichandran, Samuel Katsuyuki Shinjo, Jessica Day, Parikshit Sen, Jucier Gonçalves Junior, James B. Lilleker, Mrudula Joshi, Vishwesh Agarwal, Sinan Kardes, Minchul Kim, Marcin Milchert, Ashima Makol, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O’Callaghan, Elena Nikiphorou, Ai Lyn Tan, Tulika Chatterjee, Lorenzo Cavagna, Miguel A. Saavedra, Nelly Ziade, Johannes Knitza, Masataka Kuwana, Arvind Nune, Oliver Distler, Döndü Üsküdar Cansu, Lisa Traboco, Suryo Angorro Kusumo Wibowo, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio García-De La Torre, Chris Wincup, John D. Pauling, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta |
| Prispievatelia: | Institut Català de la Salut, [Hoff LS] School of Medicine, Universidade Potiguar (UnP), Natal, Brazil. [Ravichandran N] Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. [Shinjo SK, Junior JG] Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. [Day J] Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia. Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. Department of Medical Biology, University of Melbourne, Parkville, Australia. [Sen P] Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, India. [O'Callaghan AS] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Hoff, L. S., Ravichandran, N., Shinjo, S. K., Day, J., Sen, P., Junior, J. G., Lilleker, J. B., Joshi, M., Agarwal, V., Kardes, S., Kim, M., Milchert, M., Makol, A., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., O'Callaghan, A. S., Nikiphorou, E., Tan, A. L., Chatterjee, T., Cavagna, L., Saavedra, M. A., Ziade, N., Knitza, J., Kuwana, M., Nune, A., Distler, O., Cansu, D. U., Traboco, L., Wibowo, S. A. K., Tehozol, E. A. Z., Serrano, J. R., La Torre, I. G. -D., Wincup, C., Pauling, J. D., Chinoy, H., Aggarwal, R., Gupta, L. |
| Zdroj: | Rheumatol Int Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut instname COVAD Study Group 2023, 'COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey', Rheumatology International, vol. 43, no. 1, pp. 47-58. https://doi.org/10.1007/s00296-022-05229-7 |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2022. |
| Rok vydania: | 2022 |
| Predmety: | Adult, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación, COVID-19 Vaccines, Breakthrough Infections, Autoimmune diseases, Immunosuppressive Agents/adverse effects, Simian Acquired Immunodeficiency Syndrome, ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes, Observational Research, Autoimmune Diseases, 03 medical and health sciences, 0302 clinical medicine, Autoimmune Diseases/epidemiology, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, Autoimmune disease, Animals, Humans, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, Idiopathic inflammatory myopathie, COVID-19/epidemiology, Malalties autoimmunitàries, Myositis, Vaccination, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination, COVID-19, Middle Aged, DISEASES::Immune System Diseases::Autoimmune Diseases, Breakthrough infection, 3. Good health, SARS-CoV-2 vaccination, Cross-Sectional Studies, Female, Self Report, Idiopathic inflammatory myopathies, COVID-19 (Malaltia) - Vacunació, Immunosuppressive Agents |
| Popis: | Objectives We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). Methods This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Results Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7). Conclusions Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs. |
| Druh dokumentu: | Article Other literature type |
| Popis súboru: | application/pdf; ELETTRONICO |
| Jazyk: | English |
| ISSN: | 1437-160X |
| DOI: | 10.1007/s00296-022-05229-7 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/36271958 https://hdl.handle.net/11351/8994 https://research.manchester.ac.uk/en/publications/891f51ab-27a3-4b11-8dda-c3a4a5d326cc https://doi.org/10.1007/s00296-022-05229-7 https://research.manchester.ac.uk/en/publications/891f51ab-27a3-4b11-8dda-c3a4a5d326cc http://www.scopus.com/inward/record.url?scp=85140727930&partnerID=8YFLogxK https://doi.org/10.1007/s00296-022-05229-7 https://link.springer.com/10.1007/s00296-022-05229-7 https://www.mendeley.com/catalogue/1815c0fb-3318-350f-9dd8-b60a7e3cab19/ |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) . |
| Prístupové číslo: | edsair.doi.dedup.....a7df567c26c29d6e3cffa4d9a8b85051 |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Objectives We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). Methods This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Results Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7). Conclusions Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs. |
|---|---|
| ISSN: | 1437160X |
| DOI: | 10.1007/s00296-022-05229-7 |